SUPPLEMENT DATED 23 JULY 2024
TO THE REGISTRATION DOCUMENT OF 26 MARCH 2024

BioSenic SA (the "**Company**" or "**BioSenic**", and together with its subsidiaries "**BioSenic Group**") prepared the present supplement (the "**Supplement**"), which is supplemental to BioSenic's registration document as approved by the Belgian Financial Services and Markets Authority (*Autorité des services et marchés financiers*, the "**FSMA**") on 26 March 2024 (the "**Registration Document**"), with respect to the prospectus dated 23 July 2024 in relation to the admission to listing and trading on Euronext Brussels and Euronext Paris of up to 210,000,000 new shares of the Company (the "**New Shares**"), that may be issued by the Company upon conversion of a maximum of 210 Convertible Bonds in accordance with the terms and conditions of an issuance and subscription agreement dated 21 June 2024 between the Company and Global Tech Opportunities 15 ("**GTO 15**") (the "**Subscription Agreement**").

In order to ensure that the information contained in the Registration Document is up-to-date – as required by the Regulation (EU) 2017/1129 (the "**Prospectus Regulation**") – the Registration Document is deemed to be amended as set out below.

The English version of the Supplement was approved by the FSMA on 23 July 2024 in its capacity as competent authority under the Prospectus Regulation. The FSMA's approval does not imply any judgment on the situation of the Company. The FSMA only approves the Supplement as meeting the standards of completeness, comprehensibility and consistency imposed by Prospectus Regulation. Such approval should not be considered as an endorsement of the quality of the New Shares.

The Supplement has been translated into French. The Company is responsible for the consistency between the French and English versions of the Supplement. Without prejudice to the responsibility of the Company for the inconsistencies between the different language versions of the Supplement, in the case of discrepancies between the different versions of these supplements the English version will prevail. The Supplement will be published on the website of the Company (https://biosenic.com/) and will also be made available to investors, at no cost, at the Company's registered office. Following its approval, the Supplement, together with a French translation, will be notified by the FSMA to the AMF in France in accordance with the Prospectus Regulation, which does not imply any judgement by the AMF on the merits or the quality of the Company or the Shares.

Save as disclosed in the Supplement, there has been no other significant new factor, material, mistake or inaccuracy since the date of publication of the Registration Document.

The Board of Directors of BioSenic SA assumes responsibility for the content of the Supplement. The Board of Directors declares that the information contained in this Supplement, is to the best of its knowledge, in accordance with the facts and makes no omission likely to affect its import.

On behalf of the Board of Directors,

Prof. François Rieger
President of the Board of Directors and CEO

Véronique Pomi-Schneiter
Director and Deputy CEO

<u>This section replaces section 1.1 "Risk factors related to BioSenic Group's financial position and capital requirement" of the Registration Document</u>

a. BioSenic and its subsidiary Medsenic are clinical-stage biotechnology companies and have not yet commercialised any of their products. They have therefore incurred net losses since their inception and expect to continue to incur net losses in the foreseeable future. As a result, BioSenic Group might never achieve sustained profitability.

BioSenic is a biotechnology company exploiting the possibilities offered by the therapeutic use of arsenic salts for patients with autoimmune diseases. Currently, BioSenic Group is concentrating specifically on the development of its most advanced clinical assets, targeting markets with large unmet medical needs and limited innovation. BioSenic Group is currently involved in setting up a Phase III study for the treatment of Chronic Graft versus Host Disease (cGvHD) with a patented oral formulation of arsenic trioxide, ArsciCor, while preparing two Phase IIb studies for the treatment of moderate to severe Systemic Lupus erythematosus (SLE) and Systemic Sclerosis (SSc). As BioSenic Group is still developing its product candidates in clinical settings and has not completed the full development of any product, it does not anticipate generating revenue from sales for the foreseeable future and has incurred significant losses since the incorporation of BioSenic and Medsenic. The consolidated statement of financial position for the financial year ended 31 December 2023 of the BioSenic Group shows negative retained earnings of € 34.9 million. These losses resulted principally from costs incurred in research and development, preclinical testing, clinical development of its product candidates, the recognition of impairment expenses on intangible assets and on goodwill, as well as costs incurred for research programmes and from general and administrative expenses. In the future, BioSenic Group intends to continue its efforts to conduct preclinical testing, product development, clinical trials and regulatory compliance activities and improve product formulations and clinical delivery techniques. These activities together with anticipated general and administrative expenses will result in incurring further significant losses for several years. For next several years, BioSenic Group anticipates that its expenses and accumulated consolidated losses will increase substantially mainly due to:

1) Conducting the Phase III clinical trial with arsenic trioxide in the first-line treatment of cGvHD;

2) Preparing and partnering/conducting the Phase IIb clinical trials for SLE and SSc;

3) Expanding its pre-clinical and clinical pipeline with new indications through new technologies (definition of the molecular targets of the arsenic active ingredient (API), combination of matter formulations, nanoparticles for delivery, development of exosomes from bone marrow mesenchymal cells (ALLOB cells), in the context of new autoimmune/inflammatory pathologies or organ repair clinical opportunities).

The size of BioSenic Group's future net losses will depend, in part, on the rate of future growth of its expenses and its ability to generate revenue, mainly through out-licencing. Given that the patient recruitment for the Phase III clinical trial with arsenic trioxide in the first-line treatment of cGvHD, the Group's most advanced clinical asset, still has to start, BioSenic Group expects that it will take at least five years before market authorisation could potentially be obtained for this asset and commercialisation could start. BioSenic Group may encounter unforeseen expenses, difficulties, complications, delays and other presently unknown factors that may have a material adverse effect on its business and financial situation. BioSenic Group does not have a commercial organisation in place to launch its product candidates on its own. BioSenic Group does currently not intend to develop itself a sales and distribution organisation anywhere in the world and will rely for the distribution of its products on license and supply deals with commercial partners. Such arrangements may require BioSenic Group to incur additional expenses, increase its capital expenditures, issue securities that dilute its shareholders or disrupt its management and business. Furthermore, BioSenic Group cannot assure that it will generate positive clinical data, find licensees, receive regulatory approval, get into commercialization and earn revenues or achieve profitability, which could impair its ability to sustain operations, obtain any

required additional funding or continue as a going concern. Even if BioSenic Group achieves profitability in the future, it may not be able to sustain profitability in subsequent periods.

b. As BioSenic Group does not have cash flow generating commercial activities, it is largely dependent on external funding which may not be available on acceptable terms when needed, if at all.

On 31 December 2023, BioSenic's Group cash position amounted to € 150,000. As of 31 May 2024, BioSenic had 1.15 million euros in cash and cash equivalents (which includes the receipt of tax credits in Q2 2024). The BioSenic Group does currently not have sufficient working capital to meet its present requirements and cover the working capital needs for a period of at least 12 months as of the date of this Prospectus. For more information about current cash situation of BioSenic and Medsenic, please see Section 3 of this Registration Document and the Securities Note. BioSenic Group will require additional funding in the future to sufficiently finance its core operations and to take advantage of new business opportunities. The BioSenic Group's future financing needs will depend on many factors, including the progress, costs and timing of its research and development activities, the sustained performance (recruiting patients and generating positive results) of its clinical trials, the costs and timing of obtaining regulatory approval, the costs of obtaining, maintaining and enforcing its patents and other intellectual property rights, the costs and timing of maintaining or obtaining manufacturing for its products and product candidates, the costs and timing of establishing sales and marketing capabilities and the terms and timing of establishing additional collaborations, license agreements and other partnerships. The existing capital resources of BioSenic Group are not sufficient to fund the completion of its planned Phase III clinical trial with arsenic trioxide in the first-line treatment of cGvHD or any of its other envisaged clinical trials. Accordingly, BioSenic will need to raise significant additional funds. Currently, BioSenic Group mainly relies on equity and bond financing and intends to pursue additional funding opportunities in the future, including potentially the issuance of convertible bonds.

These material uncertainties relating to the Company's ability to access sufficient sources of financing and to continue as a going concern resulted in a disclaimer of opinion that the Company received from its statutory auditor in its audit report regarding the financial year ending on the 31 December 2023.

Please refer to Section 4.13 of this Registration Document for more information about BioSenic Group's non-dilutive financing and grants. It should in this respect be noted that changes in regional financing and grant policies, a shift in regional investment priorities or challenges by the European instances may reduce or jeopardise the Group's ability to obtain or retain non-dilutive financing, grants and/or other benefits. In addition, future growth of the BioSenic Group, whether or not including geographical expansion, could limit the Group's eligibility to obtain similar non-dilutive financing or grants. Furthermore, BioSenic Group's ability to raise additional funds will depend on financial, economic and market conditions and other factors, over which it may have no or limited control, additional funds may not be available to it, when necessary, on commercially acceptable terms, if at all. If the necessary funds are not available, BioSenic Group may need to seek funds through forced collaborations and licensing arrangements, which may require it to reduce or relinquish significant rights to its research programmes and product candidates, to grant licenses on its technologies to partners or third parties or enter into new collaboration agreements, the terms could be less favourable to BioSenic Group than those it might have obtained in a different context. If adequate funds are not available on commercially acceptable terms when needed, this could have a material adverse effect on BioSenic Group as it may be forced to delay, reduce or terminate the development or commercialisation of all or part of its product candidates or it may be unable to take advantage of future business opportunities. For more information on BioSenic Group's working capital, please see the Securities Note.

On 10 June 2024, the Enterprise Court of Nivelles BioSenic homologated the Company's proposed debt restructuring plan covering the years 2024-2029 which was introduced on the basis of article XX83/22 and following of the Belgian Code on Economic Law and approved by the creditors on 27 May 2024. The full details of the debt restructuring plan are available on the Company's website: https://biosenic.com/sites/default/files/2024-04/PRJ_BioSenic_FR.pdf. As a result of the debt restructuring plan the loans previously provided by Monument, Patronale and EIB for a total principal amount of

EUR 15.5 million will be extended to 31 December 2030, with the possibility to further extend the maturity date by up to 24 additional months provided that if the total cash balance of the Company as of 31 December 2030 is less than EUR 15 million. The existing debts with ordinary creditors, including debts relating to the development of ALLOB and JTA, have been reduced by 95% and extended by 5 years. Depending on the type of debt, the restructuring plan also provides for a discount and/or extension of payment date for the other creditors of the Company, as further described in the restructuring plan.

The agreements that the Company reached in September 2023 with Patronale, Monument and the EIB for the restructuring of its aforementioned financial debts for an outstanding total principal amount of EUR 15.5 million, were conditional upon BioSenic raising sufficient new equity to support its R&D plans (including the Phase III clinical trial of its lead Oral ATO therapeutic candidate targeting cGvHD). The in principle agreement of the EIB remained subject to the EIB's internal credit approval. The Homologation Judgement of 10 June 2024 has removed the condition of raising sufficient new equity and has declared the agreed terms with Patronale, Monument and EIB fully binding. The court also ruled on the maximum amount of legal costs that the Company will need to reimburse to EIB, which was an ongoing point of discussion between parties. However, the binding terms agreed with aforementioned lenders still need to be reflected in final agreements and implemented (including the actual issuance of the new convertible bonds to Patronale and Monument), the timing of which is still uncertain.

On 21 June 2024, the Company entered into the new Subscription Agreement with GTO 15. Under the terms of this new Subscription Agreement, GTO 15 agreed to make available to the Company a Convertible Bond funding program for a total amount of up to EUR 2.1 million to be drawn down for the full amount by the way of the issuance of a maximum of 210 Convertible Bonds with a nominal value of EUR 10,000 each (to be fully paid up in cash at the time of subscription). The Convertible Bonds will be subscribed for by GTO 15 in seven tranches of EUR 300,000 each (each such tranche including 30 Convertible Bonds). Between each tranche, from the third tranche onwards, there will be a cool down period of 20 trading days with respect to each remaining tranche. The Company agreed to drawdown up to one tranche on the demand of GTO 15. As from the second tranche, the 20-day average daily value traded – trimmed for 10% of the outliers (meaning the data points from the top and bottom tails) – must be greater than EUR 20,000 prior to the disbursement of the tranche. Furthermore, as from the fourth tranche onwards, in order to exercise further tranches, BioSenic's should have secured additional equity funding for a minimum amount of EUR 800,000. The Convertible Bonds are non-interest bearing, unsecured and subordinated to the existing loan granted to the Company by the EIB pursuant to the loan agreement dated 30 June 2021.

The term sheet signed in December 2023 with TrialCap Pte. Ltd. provides that the two term loan notes of each up to USD 4 million are conditional upon BioSenic raising sufficient equity in an amount allowing the Company to start the Phase III clinical trial in cGvHD (currently estimated around €2 million to €3 million). If the Company will not be able to raise sufficient equity, which is not certain, this may prevent the implementation of one or both of the up to USD 4 million term loan notes previously agreed upon with TrialCap Pte. Ltd. As the Company heavily depends on such term loan notes to finance its future working capital needs, the impossibility to complete one or both of the envisaged term loan notes would have a material adverse impact on the BioSenic Group, and its shareholders leading to the potential total loss of their entire investment.

The volatility on the financial markets caused by the increased global geopolitical tension may hinder raising necessary funding on the financial markets. As the BioSenic Group does currently not have sufficient working capital to meet its present requirements and cover the working capital needs for a period of at least 12 months, it depends on the financial markets to organise its future funding operations (in the form of placements of shares or (convertible) bonds). Volatile financial markets might make such funding operations more difficult or impossible, or might force BioSenic Group to complete the operations on less advantageous terms (for instance triggering additional dilution for the shareholders).

This paragraph replaces paragraphs two and three of risk factor 1.6, b, "Should BioSenic Group be unable to obtain new license rights on reasonable terms, or if it would lose any of its licenses or otherwise experiences disruptions to its business relationship with its licensors, BioSenic Group might be unable to develop, manufacture or sell its products" of the Registration Document:

Under the current license agreement with Phebra (as amended in July 2024), the license agreement grant is subject to Medsenic's ability to secure sufficient funding before 31 May 2026 to commence a clinical study using OATO. If BioSenic Group is not able to secure the necessary funding to commence a clinical study using Phebra OATO (i.e., allowing completion of the IND application with the FDA, and starting CRO preparation, sites selection and data collection for the clinical study) by 31 May 2026, Phebra has the right to terminate the license agreement with Medsenic. For more information on the license agreement and the marketing and supply agreements with Phebra, please revert to Section 6.4.4.2. A termination of the license agreement with Phebra or a renewal of the license agreement on commercially unfavourable terms could substantially impair BioSenic Group's ability to generate sufficient future revenues from its existing clinical programmes, which would have an adverse impact on its valuation and possibility its ability to raise additional funding thereby threatening BioSenic Group's ability to continue as a going concern.

This section replaces Section 3.1 "Information incorporated by reference" of the Registration Document:

This Registration Document shall be read and construed in conjunction with the following documents:

(i) the annual report and audited consolidated financial statements of BioSenic prepared in accordance with IFRS for the financial year ended 31 December 2023 (in English and French), together with the related audit report thereon (available via the following hyperlinks https://biosenic.com/sites/default/files/2024-06/20240606_AnnualReport2023_EN_final.pdf; https://biosenic.com/sites/default/files/2024-06/2024-06-06_AnnualReport2023_FR_final.pdf).

Copies of documents incorporated by reference in this Registration Document may be obtained (without charge) from the registered offices of BioSenic and the website of BioSenic (https://biosenic.com/investors).

The tables below include references to the relevant pages of the audited consolidated financial statements of BioSenic for the financial year ended 31 December 2023, as set out in the annual reports of BioSenic (in English and French). Information contained in the documents incorporated by reference other than information listed in the tables below is either not relevant for the investor or covered elsewhere in the Registration Document.

Audited consolidated financial statements of BioSenic prepared in accordance with IFRS for the financial period ended 31 December 2023, as set out in the annual report (in English and French).	
Business overview	p. 10 - 20
Financial review of the year ending 31 December 2023	p. 23 - 27
Consolidated statement of financial position	p. 77
Consolidated statement of comprehensive income	p. 78
Consolidated statement of cash flows	p. 79
Consolidated statement of changes in equity	p. 80
Notes to the consolidated financial statements	p. 81 - 121
Auditor' s report	p. 72 - 76

This section replaces Section 3.5 "Significant change in the financial position of the BioSenic Group since 31 December 2022" of the Registration Document:

3.5 Significant change in the financial position of the BioSenic Group since 31 December 2023

On 8 January 2024, the Company entered into a new issuance and subscription agreement with GTO 15. Under the terms of the subscription agreement, GTO 15 agreed to make available to the Company a convertible bond funding program for a total amount of up to €1.2 million to be drawn down for the full amount by the way of the issuance of a maximum of 120 convertible bonds with a nominal value of €10,000 each (to be fully paid up in cash at the time of subscription). The convertible bonds have been fully subscribed for by GTO 15 in four tranches of €300,000 each (each such tranche including 30 convertible bonds). The convertible bonds are non-interest bearing, unsecured and subordinated to the existing loan granted to the Company by the European Investment Bank pursuant to the loan agreement dated 30 June 2021.

On 6 February 2024, BioSenic raised €500,000 in gross proceeds through a private placement of 12,195,120 new shares at an issue price of €0,041 per share with institutional investors, Gestys Santé Biotech and Friedland Gestion.

On 10 June 2024, the Enterprise Court of Nivelles BioSenic homologated the Company's proposed debt restructuring plan covering the years 2024-2030 which was introduced on the basis of article XX83/22 and following of the Belgian Code on Economic Law. The full details of the debt restructuring plan are available on the Company's website: https://biosenic.com/sites/default/files/2024-04/PRJ_BioSenic_FR_0.pdf.

On 21 June 2024, the Company entered into a new issuance and subscription agreement with GTO 15. Under the terms of this new subscription agreement, GTO 15 agreed to make available to the Company a convertible bond funding program for a total amount of up to €2.1 million to be drawn down for the full amount by the way of the issuance of a maximum of 210 convertible bonds with a nominal value of €10,000 each (to be fully paid up in cash at the time of subscription). The convertible bonds will be subscribed for by GTO 15 in seven tranches of €300,000 each (each such tranche including 30 convertible bonds). Between each tranche, from the third tranche onwards, there will be a cool down period of 20 trading days with respect to each remaining tranche. The Company agreed to drawdown up to one tranche on the demand of GTO 15. As from the second tranche, the 20-day average daily value traded – trimmed for 10% of the outliers (meaning the data points from the top and bottom tails) – must be greater than €20,000 prior to the disbursement of the tranche. Also, the completion of an equity raise (with a minimum amount of €800,000) by BioSenic is a condition as per the fourth tranche of €300,000. The convertible bonds are non-interest bearing, unsecured and subordinated to the existing loan granted to the Company by the European Investment Bank pursuant to the loan agreement dated 30 June 2021.

This section replaces Section 3.6 "Current cash situation" of the Registration Document:

BioSenic Group does currently not have sufficient working capital to meet its present requirements and cover the working capital needs for a period of at least 12 months as of the date of this Securities Note.

As of 31 May 2024, BioSenic had 1.15 million euros in cash and cash equivalents (which includes the receipt of the tax credits in Q2 2024). The Company is in the process of closing the ALLOB Phase IIb clinical trial, with many actions to be carried out to follow up the last patients recruited at the end of 2022 and the beginning of 2023, as well as the regulatory closure of the 24 European centers involved. BioSenic anticipates having sufficient cash to complete the IND application with the FDA and to start the CRO preparation, sites selection and data collection for the Phase III clinical trials in cGvHD, considering the following relevant assumptions:

- A drawdown of three tranches under the new Convertible Bonds funding program with GTO 15 in 2024. There is a liquidity condition from the second tranche onwards, namely the 20-day average daily value traded – trimmed for 10% of the outliers (meaning the data points from the top and bottom tails) – must be greater than EUR 20,000 prior to the disbursement of the tranche. As from the fourth tranche onwards, in order to draw down further tranches, BioSenic's should have secured additional equity funding for a minimum amount of EUR 800,000. GTO 15 may also terminate the financing

program int the case of an event of default, which includes customary events such as non-cured default under the Subscription Agreement, de-listing of the Company's Shares, a cross-default in relation to other financial debts of the Company and events that have a material adverse effect on the Company (taking into account the Company's consolidated net asset value or share price).

- Finalisation and implementation of the key terms that were agreed with certain key historical creditors of the Company (i.e., Monument, Patronale and EIB) and as homologated and declared binding as part of the 2024-2029 debt restructuring plan by the Enterprise Court of Nivelles on 10 June 2024, to postpone the maturity date and interest payments of the ongoing loans for an aggregate principal amount of EUR 15.5 million.
- BioSenic signed a term sheet in December 2023 with TrialCap Pte. Ltd. for a proposed debt and equity financing. In accordance with the term sheet, two term loan notes of each up to USD 4,000,000 will be provided to BioSenic, as well as an equity investment of USD 800,000 in new shares of BioSenic. BioSenic is seeking the funds to continue its clinical development. The final agreement with TrialCap Pte. Ltd to subscribe for the loan notes is being discussed, but still needs to be finalised and signed (including by a newly incorporated Australian subsidiary of Medsenic). It is currently expected that funding under the loan note subscription agreement will be subject, among other, to the following conditions precedent: (i) the completion of an equity raise in an amount allowing the Company to start the Phase III clinical trial in cGvHD (currently estimated around €2 million to €3 million), (ii) the signing of a contract for completing the Phase III clinical trial in cGvHD with a Clinical Research Organization ("CRO"), (iii) obtaining necessary authorisations to conduct the Phase III clinical trial in cGvHD and to receive refundable tax offsets ("RTOs").
- A successful equity fundraising.
- A reinforced strict policy of cost management.

All of the above circumstances and events are however subject to material uncertainties, which may cast significant doubt about the Company's ability to continue as a going concern. Indeed, given that the company is expected to have sufficient cash until the beginning of the fourth quarter of 2024 (assuming the use of three tranches from the new convertible bonds program with GTO 15 but without the potential proceeds of a new equity raise), BioSenic Group will need to raise additional financing to continue its operations in the longer term. These material uncertainties relating to the Company's ability to access sufficient sources of financing and to continue as a going concern resulted in a disclaimer of opinion that the Company received from its statutory auditor in its audit report regarding the financial year ending on the 31 December 2023.

BioSenic Group expects for 2024 to use the proceeds of anticipated future debt and equity fundraisings in priority for progressing the Phase III clinical trial in cGvHD. As a result, it will only be possible to start the SLE and SSc Phase IIb clinical trials if the BioSenic Group succeeds in concluding a strong partnership with a biopharmaceutical company or if it manages to successfully out-license some of its technology.

BioSenic Group's ability to complete the milestones in the development of OATO with cGvHD during the 12-month period starting from the date of this Securities Note will be put at risk if it is not able to raise additional funding of approximately EUR 5.6 million at acceptable terms during such 12-month, which is uncertain. If Biosenic Group would not be able to finalise and implement the new equity and debt financing with TrialCap Pte. Ltd as currently expected, the working capital shortfall during the 12-month period starting from the date of this Securities Note and to be covered via additional funding would amount to EUR 7.7 million. Furthermore, if BioSenic is not able to access available funding due to the conditions attached thereto or to secure the additional funding as described in this paragraph, its ability to continue as a going concern would be threatened, which could lead to its liquidation or bankruptcy and which would have a material adverse impact on BioSenic Group, and its securities holders leading to the potential total loss of their entire investment.

If all 210 non-interest bearing, unsecured and subordinated Convertible Bonds with a total commitment of EUR 2.1 million to be issued by BioSenic to GTO Opportunities 15 in accordance with the Subscription Agreement, have been subscribed for the aggregate amount of EUR 2.1 million and if BioSenic is not in breach of the Subscription Agreement with GTO 15 in any material respect, BioSenic has the option to renew the EUR 2.1 million program prior to 21 December 2025.

This section replaces Section 4.1 "Important recent events in the development of BioSenic Group's business" of the Registration Document:

Key Milestones of BioSenic	
YEAR 2023	
Corporate	• Appointment of Dr Carole Nicco as Chief Scientific Officer. • Appointment of Mr Yves Sagot as Independent Director. • BioSenic received EUR 1 million (minus 6% taxes) Pregene as a settlement following the termination by Pregene of the exclusive license agreement entered into between BioSenic, Pregene and Link Health Pharma. • Appointment of Lieven Huysse, MD as Chief Medical Officer. • Agreement with Patronale, Monument and the European Investment Bank for the restructuring of BioSenic's key financial debts.
ALLOB	• Optimization of ongoing Phase IIb clinical trial ALLOB and completion of patient recruitment. • BioSenic and Pluristyx sign term sheet for market availability of ALLOB mesenchymal cells. • BioSenic puts Phase IIb ALLOB trial on hold following negative results obtained for the primary endpoint (mid-June).
JTA	• Post-hoc analysis of the results of its Phase III trial of JTA-004 targeting knee osteoarthritis in the subset of patients with the most painful and inflammatory form of knee osteoarthritis shows a pain-relieving effect of JTA-004 not only superior to placebo but also to the active comparator. • BioSenic reacquired intellectual property rights to JTA-004 from the Walloon region.
Immune diseases	• Publication of data providing additional details about the mechanism of action of its lead API arsenic trioxide (ATO) to prevent autoimmune diseases published in the peer-reviewed paper *Frontiers in Immunology*[1]. • BioSenic received a key European patent from EPO, for further therapeutic development in cancer, infectious and immune disease covering the therapeutic use of a new composite formulation of anti-inflammatory compounds with unique advantages. • BioSenic identifies key biomarkers for cGvHD and submits patent to EPO. • Amendment of the license agreement between Medsenic SAS and Phebra Pty Ltd to extend the deadline for securing the necessary funding to commence the phase 3 clinical trial of OATO for the treatment of cGvHD from 31 May 2023 to 31 May 2024. • BioSenic received a Chinese patent protecting the combined use of metal ions and arsenic salts to treat a wide range of serious diseases. • Publication of data providing additional key indications of arsenic trioxide (ATO) to treat systemic sclerosis (SSc) in a peer-reviewed international journal[2]. • BioSenic completed a post-hoc analysis of its phase 2 clinical trial of ATO, finding the best scheme for administration of oral arsenic trioxide for an efficient treatment of cGvHD.

[1] Charlotte Chêne, Dominique Rongvaux-Gaïda, Marine Thomas, François Rieger, Carole Nicco, Frédéric Batteux "Optimal combination of arsenic trioxide and copper ions to prevent autoimmunity in a murine HOCl-induced model of systemic sclerosis", in *Front. Immunol.*, 30 March 2023, Volume 14. Link: https://www.frontiersin.org/articles/10.3389/fimmu.2023.1149869/full.

[2] Anne Cauvet, Arthur Decellas, Christophe Guignabert, Dominique Rongvaux-Gaïda, Raphaël Thuillet, Mina Ottaviani, Ly Tu, François Rieger, Jérôme Avouac and Yannick Allanore, "Arsenic trioxide demonstrates efficacy in a mouse model of preclinical systemic sclerosis". *Arthritis Res Ther* 25, 167 (2023). https://doi.org/10.1186/s13075-023-03143-2.

	• BioSenic signed (end of H2) a term sheet with Singapore based TrialCap Pte. Ltd. and/or other lenders for a proposed debt and equity financing. BioSenic is seeking the funds to continue its clinical development, backed by previous encouraging Phase 2 and pre-clinical results of arsenic trioxide (ATO).
YEAR 2024	
Corporate	• BioSenic signed a new subscription agreement for a maximum EUR 1.2 million convertible bonds facility, arranged by ABO Securities through its affiliated entity GTO 15. • Promotion of Dr Carole Nicco to Chief Operating Officer (COO) in addition to her position as Chief Scientific Officer (CSO). • BioSenic raises €500,000 in private placement of new shares with established new investors. • BioSenic has received the homologation judgment for the restructuring plan filed with the Enterprise Court of Nivelles, making it binding on all deferred creditors, and the measures provided for therein will continue until June 2029, the end of the five-year period set by law. • BioSenic signed a third subscription agreement for a maximum EUR 2.1 million convertible bonds facility, arranged by ABO Securities through its affiliated entity GTO 15.
JTA	• BioSenic filed a U.S. patent for JTA-004, a viscosupplement in late-stage clinical development, following new evidence of its efficacy in a recently defined subtype of osteoarthritis (OA).
Immune diseases	• BioSenic's subsidiary, Medsenic SAS, signed a global licensing, supply and commercialization agreements with Phebra Pty Ltd. related to the adaptation of the License Agreement and the MDA signed earlier in May 2021, when Phebra became a minority shareholder in Medsenic SAS. • BioSenic received a patent by the Canadian Intellectual Property Office to expand protection of the arsenic trioxide (ATO) platform. • BioSenic filed the continuation patent application US 18/763,376 with the United States Patent & Trademark Office (USPTO) to provide protection for the use of arsenic trioxide (ATO) for the prevention and treatment of sepsis syndrome.

This section replaces Section, 4.10.2.2 "License agreement and marketing and supply agreement with Phebra" of the Registration Document:

BioSenic's subsidiary, Medsenic, and Phebra entered into (i) a license agreement on 21 May 2021 and (ii) a marketing and supply agreement on 31 May 2021 for the oral formulation of arsenic trioxide in the following indications: Graft Versus Host Disease, Systemic Sclerosis, Systemic Lupus Erythematosus, infectious diseases related to COVID-19 and CNS inflammatory diseases related to Multiple Sclerosis. In consideration for the license, Phebra received 3,151 shares (4.3% of the shares currently outstanding) in Medsenic. On 2 July 2024, the Company announced the signature of global licensing, supply and commercialization agreements between Medsenic and Phebra modifying the agreements signed in May 2021. The new license provides for a royalty on worldwide sales to Phebra, which simplifies and facilitates the terms and conditions for possible sublicensing to future external partners. In addition, under the license agreement, Phebra agrees that Medsenic will have exclusive worldwide territorial rights for the use of OATO in GvHD. Commercial arrangements for other indications in the initial licence agreement remain unchanged. With respect to the marketing and supply agreement, Phebra remains responsible for maintaining and updating the drug substance file to comply with the regulation of all active territories; for controlling the compliance with various regulatory authorities on ongoing supplier approval and compliance with good manufacturing practices (GMP) requirements; for updating the drug master file of OATO; for managing the contract manufacturing organization (CMO) and supply chain of the active pharmaceutical ingredient for the clinical release of the product; and for covering the regulatory and quality and GMP expenses. In addition, Medsenic will have the right to establish an Australian entity to use the OATO patents for the cGvHD indication. The Australian entity will not commercially

compete with Phebra Pty Ltd., particularly in the field of APL (acute promyelocytic leukemia) cancer treatment, by producing Medsenic's GvHD treatment in indication-specific packaging. Please revert to Section 6.4.4.2 of this Registration Document for more information about the agreements with Phebra.

This section replaces Section, 4.11 "Partnerships" of the Registration Document:

Medsenic and Phebra entered into (i) a license agreement on 21 May 2021 and (ii) a marketing and supply agreement on 31 May 2021 for the oral formulation of arsenic trioxide in the following indications: Graft Versus Host Disease, Systemic Sclerosis, Systemic Lupus Erythematosus, infectious diseases related to COVID-19 and CNS inflammatory diseases related to Multiple Sclerosis. On 2 July 2024, the Company announced the signature of global licensing, supply and commercialization agreements between Medsenic and Phebra modifying the agreements signed in May 2021. The license provides for a royalty on worldwide sales to Phebra, which simplifies and facilitates the terms and conditions for possible sublicensing to future external partners. In addition, under the license agreement, Phebra agrees that Medsenic will have exclusive worldwide territorial rights for the use of OATO in GvHD. Commercial arrangements for other indications in the initial licence agreement remain unchanged. With respect to the marketing and supply agreement, Phebra remains responsible for maintaining and updating the drug substance file to comply with the regulation of all active territories; for controlling the compliance with various regulatory authorities on ongoing supplier approval and compliance with good manufacturing practices (GMP) requirements; for updating the drug master file of OATO; for managing the contract manufacturing organization (CMO) and supply chain of the active pharmaceutical ingredient for the clinical release of the product; and for covering the regulatory and quality and GMP expenses. In addition, Medsenic will have the right to establish an Australian entity to use the OATO patents for the cGvHD indication. The Australian entity will not commercially compete with Phebra Pty Ltd., particularly in the field of APL (acute promyelocytic leukemia) cancer treatment, by producing Medsenic's GvHD treatment in indication-specific packaging. Please revert to Section 6.4.4.2 of this Registration Document for more information about the agreements with Phebra.

This section replaces Section 5.4 "Board of Directors" of the Registration Document:

Section 5.4 has been updated as a result of the annual report for the financial year ended 31 December 2023, which is available on the BioSenic's website via the following hyperlink: https://biosenic.com/sites/default/files/2024-06/20240606_AnnualReport2023_EN_final.pdf (the "**Annual Report 2023**"). Please find the update in Section 4.3 "Board of Directors" of the Annual Report 2023, which is included herein by reference.

This section replaces Section 5.5 "Executive Committee" of the Registration Document:

Section 5.5 has been updated as a result of the Annual Report 2023: please find the update in Section 4.4 "Executive Committee" of the Annual Report 2023, which is included herein by reference.

This section replaces Section 6.4.4.2, a, "Medsenic's transaction with Phebra PTY Ltd." of the Registration Document:

BioSenic's subsidiary, Medsenic, and Phebra entered into (i) a license agreement on 21 May 2021 and (ii) a marketing and supply agreement on 31 May 2021 for the oral formulation of arsenic trioxide ("OATO") in the following indications: Graft Versus Host Disease (GvHD), Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE), infectious diseases related to COVID-19 and CNS inflammatory diseases related to Multiple Sclerosis (referred to as Multiple Sclerosis). In consideration for the license, Phebra received 3,151 shares (4.3% of the shares currently outstanding) in Medsenic.

On 2 July 2024, the Company announced the signature of global licensing, supply and commercialization agreements between Medsenic and Phebra modifying the agreements signed in May 2021. The license provides for a royalty on worldwide sales to Phebra, which simplifies and facilitates the terms and conditions for possible sublicensing to future external partners. In addition, under the license agreement, Phebra agrees that Medsenic will have exclusive worldwide territorial rights for the use of OATO in GvHD. Commercial arrangements for other indications in the initial licence agreement remain unchanged. With respect to the

marketing and supply agreement, Phebra remains responsible for maintaining and updating the drug substance file to comply with the regulation of all active territories; for controlling the compliance with various regulatory authorities on ongoing supplier approval and compliance with good manufacturing practices (GMP) requirements; for updating the drug master file of OATO; for managing the contract manufacturing organization (CMO) and supply chain of the active pharmaceutical ingredient for the clinical release of the product; and for covering the regulatory and quality and GMP expenses. In addition, Medsenic will have the right to establish an Australian entity to use the OATO patents for the cGvHD indication. The Australian entity will not commercially compete with Phebra Pty Ltd., particularly in the field of APL (acute promyelocytic leukemia) cancer treatment, by producing Medsenic's GvHD treatment in indication-specific packaging.

Under the license agreement with Phebra (as amended in July 2024), the license agreement grant is subject to Medsenic's ability to secure sufficient funding before 31 May 2026 to commence a clinical study using OATO. If BioSenic Group is not able to secure the necessary funding to commence a clinical study using Phebra OATO (i.e., allowing completion of the IND application with the FDA, and starting CRO preparation, sites selection and data collection for the clinical study) by 31 May 2026, Phebra has the right to terminate the license agreement with Medsenic.